Post-Marketing Study Deadlines Urged As House Tackles FDA Safety Effort
Executive Summary
FDA should revisit the post-marketing studies that firms have outstanding, eliminate many of them, and set firm deadlines for the remaining trials, academics suggested at a March 22 hearing by the House Energy and Commerce/Oversight and Investigations Subcommittee
You may also be interested in...
Profile Of A Drug Safety Scandal: Avandia Appears Headed Down Familiar Path
With FDA planning an advisory committee review and Congress calling for hearings, the detection of a cardiovascular safety signal for GlaxoSmithKline's type 2 diabetes therapy Avandia has all the hallmarks of a classic drug safety scandal
Profile Of A Drug Safety Scandal: Avandia Appears Headed Down Familiar Path
With FDA planning an advisory committee review and Congress calling for hearings, the detection of a cardiovascular safety signal for GlaxoSmithKline's type 2 diabetes therapy Avandia has all the hallmarks of a classic drug safety scandal
Restricted Distribution Should Be Limited To Drugs With Unique Benefit – FDA
Risk management plans that include restricted distribution components should be limited to products that offer a unique benefit in a specific group of patients, according to FDA